Henri G.

His work spans both solid tumors and hematologic malignancies, targeting advanced disease stages and rare cancer subtypes.

• Advanced carcinoma of the lung and breast
• Relapsed/refractory lymphoma including diffuse large B‑cell
• Metastatic colorectal cancer with molecular profiling
• Rare sarcomas and neuroendocrine tumors

Efforts concentrate on integrating targeted therapies and immunotherapies into standard oncologic care.

He investigates acute and chronic heart conditions together with metabolic risk factors that drive cardiovascular events.

• Acute coronary syndrome management in emergency settings
• Optimizing therapy for heart failure with preserved ejection fraction
• Prevention strategies for atherosclerotic cardiovascular disease
• Control of hypertension and type 2 diabetes in high‑risk populations

Clinical studies emphasize early intervention and personalized risk reduction.

His research addresses systemic immune dysregulation across multiple organ systems.

• Systemic lupus erythematosus and lupus nephritis
• ANCA-associated vasculitis treatment pathways
• Primary Sjögren's syndrome with glandular involvement
• Inflammatory bowel disease, including Crohn's disease and ulcerative colitis
• Rheumatoid arthritis and axial spondyloarthritis

Studies aim to refine biologic and small‑molecule approaches for refractory disease.

He contributes to the understanding and therapy of inherited and ultra‑rare conditions.

• Transthyretin amyloidosis with polyneuropathy and cardiomyopathy
• Hereditary metabolic disorders such as Friedreich ataxia
• Spinal muscular atrophy across pediatric and adult cohorts
• Genetically mediated renal diseases including APOL1‑associated nephropathy

Efforts focus on novel disease‑modifying agents and genotype‑guided clinical care.